OxyContin Buyers Resolve Purdue Antitrust Claims

By Allison Grande

Law360, New York (March 08, 2010, 6:37 PM ET) -- Six plaintiffs seeking to certify indirect purchaser classes in multidistrict litigation accusing Purdue Pharma LP of excluding generic competition for the painkiller OxyContin by engaging in sham patent infringement litigation have resolved their claims with the drugmaker.

In separate stipulations filed Monday in the U.S. District Court for the Southern District of New York, the Connecticut Citizen Action Group, along with five individual OxyContin consumers, agreed to dismiss their complaints with prejudice, with all parties to bear their own costs and attorneys' fees.

Additional details of...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles